while experts we interviewed who reviewed fdas march 2010 guidance noted that it addressed key principles, most identified additional technical issues that they would have liked this guidance to have addressed. for example the march 2010 guidance does not address how the use of a surrogate endpoint impacts the design and interpretation of a non inferiority trial.